US-based biopharmaceutical company Incyte has commenced its Phase II REACH-1 pivotal trial of ruxolitinib (Jakafi) combined with corticosteroids to treat steroid-refractory acute graft-versus-host disease (GVHD).

Developed in collaboration with Novartis, Incyte’s ruxolitinib is an orally administered janus kinase (JAK) inhibitor, which triggers decrease in levels of inflammatory cytokines, IL-6 and TNF-α.

It has been approved by the US Food and Drug Administration (FDA) to treat people with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also used to treat intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.

The Single-cohort Phase II trial is a part of the REACH clinical trial programme intended to test the efficacy of ruxolitinib combined with corticosteroids to treat GVHD.

"We look forward to building on the clinical evidence to date for ruxolitinib and working with regulators to help address the urgent needs of these patients."

Incyte chief medical officer Steven Stein said: “We are very pleased to have the first patient treated in the pivotal trial programme for ruxolitinib in GVHD, a severe and often life-threatening condition for which there are currently no approved treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

“We look forward to building on the clinical evidence to date for ruxolitinib and working with regulators to help address the urgent needs of these patients.”

The study has enrolled an estimated 70 patients.

It is primarily focused on determining the overall response rate triggered by the combination after 28 days of treatment.

The secondary endpoints of the trial are to determine duration of response, overall response rate at day 14, 56, and 100, non-relapse mortality and safety.